Efficacy and Safety of Tenapanor on Hyperphosphatemia in Japanese Hemodialysis Patients: Results of a Randomized Phase 3 Trial

被引：0
|
作者：
Fukagawa, Masafumi [1 ]
Ikejiri, Kazuaki [2 ]
Kinoshita, Jun [2 ]
Nakanishi, Kaoru [2 ]
Akizawa, Tadao [3 ]
机构：
[1] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan
[2] Kyowa Kirin Co Ltd, Tokyo, Japan
[3] Showa Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
TH-PO160
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [21] Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
    Fumihiko Koiwa
    Akira Terao
    Clinical and Experimental Nephrology, 2017, 21 : 513 - 522
  • [22] HOSPITALIZATION IN PATIENTS RECEIVING MAINTENANCE DIALYSIS WITH HYPERPHOSPHATEMIA RANDOMIZED TO TENAPANOR OR SEVELAMER
    Stephenson, B.
    Chertow, G.
    Yang, Y.
    Rosenbaum, D.
    VALUE IN HEALTH, 2021, 24 : S234 - S234
  • [23] Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis
    El Borolossy, Radwa
    El Wakeel, Lamia Mohamed
    El Hakim, Ihab
    Sabri, Nagwa
    PEDIATRIC NEPHROLOGY, 2016, 31 (02) : 289 - 296
  • [24] Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis
    Radwa El Borolossy
    Lamia Mohamed El Wakeel
    Ihab El Hakim
    Nagwa Sabri
    Pediatric Nephrology, 2016, 31 : 289 - 296
  • [25] EFFICACY AND SAFETY OF MODIFIED RELEASE NICOTINAMIDE IN THE TREATMENT OF HYPERPHOSPHATEMIA IN HEMODIALYSIS PATIENTS
    Ketteler, Markus
    Zidek, Walter
    Karus, Michael
    Hellmann, Burkhard
    Ammer, Richard
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 267 - 267
  • [26] Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
    Nitta, Kosaku
    Itoyama, Saki
    Ikejiri, Kazuaki
    Kinoshita, Jun
    Nakanishi, Kaoru
    Fukagawa, Masafumi
    Akizawa, Tadao
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (11): : 2243 - 2253
  • [27] One Year Efficacy and Safety of Lanthanum Carbonate for Hyperphosphatemia in Japanese Chronic Kidney Disease Patients Undergoing Hemodialysis
    Shigematsu, Takashi
    THERAPEUTIC APHERESIS AND DIALYSIS, 2010, 14 (01) : 12 - 19
  • [28] Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial
    Takahara, Yuki
    Matsuda, Yoshimi
    Takahashi, Shunichi
    Shigematsu, Takashi
    CLINICAL NEPHROLOGY, 2014, 82 (03) : 181 - 190
  • [29] Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
    Koiwa, Fumihiko
    Terao, Akira
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (03) : 513 - 522
  • [30] Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients
    Iwasaki, Y
    Takami, H
    Tani, M
    Yamaguchi, Y
    Goto, H
    Goto, Y
    Goto, Y
    Shigematsu, T
    THERAPEUTIC APHERESIS AND DIALYSIS, 2005, 9 (04) : 347 - 351
12345